Initially, the focus will be on ingredients with high exploitation and abuse potential, which TTC said will allow the leveraging of the firm's accumulated category, supply chain and quality systems expertise. The release notes that TTC will "quickly undertake an effective plan in emerging categories such as collagen, mushroom, and the science and IP of CBD [cannabidiol] that could be ripe for exploitation or that need to address potentially challenging issues."
TTC CEO Len Monheit said in the release, "We are pleased with the evolving engagement and workplans in place for prebiotics and curcumin, and know we are helping change conversations and perceptions that will protect and grow those categories. We recognized that we needed a slightly different model that is even more scalable, leverages the different issues in emerging categories, and works on areas where consensus is possible, at the same time avoiding some of the more contentious, 'political' issues."
Related: On the horizon: 2020 Forecast Washington Post Reports on Amazon CBD Sales 64% of Supplement Users Take A Supplement Daily, According to TTC Survey
For the past few years, according to the release, TTC has been collecting consumer and other insights across many categories, giving the firm a unique data set and perspective representing a significant proportion of the growth potential of the global health and nutritional products marketplace.Related: The Dietary Supplement Consumer Bill of Rights CBD – When it stands for Cannot Be Denied
